Despite considerable effort to identify susceptibility loci for schizophrenia, none have been localized. Multiple genome scans and collaborative efforts have shown evidence for linkage to regions on chromosomes 1q, 5q, 6q, 8p, 13q, 10p and 22q.
The present study was designed to elucidate potential genetic linkage heterogeneity as reported in our genome scan for schizophrenia susceptibility loci 7 and to determine whether additional regions could be identified in a stratified analysis. Previously, we showed strong linkage to chromosomes 13q32 (D13S174) (P = 0.00002) and 8p21 (D8S1771) (P = 0.0001) in 54 multiplex pedigrees using non-parametric statistical methods for a narrow phenotype (schizophrenia or schizoaffective disorder). Parametric linkage analyses provided additional support for these regions with heterogeneity models providing the best fit. Modest support (P Ͻ 0.01) for three other regions was noted: chromosomes 7q11, 14q13 and 22q11.
In a first step to reduce genetic heterogeneity, only those families clearly of European Caucasian descent were included in new analyses. Six pedigrees were omitted due to varied non-Caucasian ethnic backgrounds.
Investigators of complex disease have addressed genetic heterogeneity with some success using clinical information to stratify data. [10] [11] [12] Given the evidence from family and twin studies that first-degree relatives of individuals with schizophrenia have an increased risk for schizophrenia, schizophrenia spectrum personality disorders (schizoid, schizotypal and paranoid personality disorders) and psychotic affective disorders (major depression and bipolar disorder with psychotic features), [13] [14] [15] [16] 48 pedigrees were stratified according to the presence of these disorders in the unaffected first degree relatives (ie, relatives not diagnosed as having either schizophrenia or schizoaffective disorder). Consensus psychiatric diagnoses on all schizophrenic subjects as well as their participating first and second degree relatives had been completed. Twelve pedigrees were identified where these related phenotypes were diagnosed in 26 first-degree relatives; six pedigrees with 16 subjects diagnosed with psychotic affective disorders (PAD) and seven pedigrees with 10 subjects diagnosed with schizophrenia spectrum personality disorders (SSPD) (in one pedigree both diagnoses occurred). We tested the impact of including these relatives in expanded definitions of the affected phenotype for critical regions. (Previously, these individuals were considered phenotype unknown.) In the remaining 36 pedigrees, PAD and SSPD diagnoses were not found in participating relatives. Three strata were defined for recomputed genome scans; SSPD pedigrees, PAD pedigrees, and Other pedigrees (Table 1) .
Genotypes at 452 polymorphic loci were re-analysed for evidence of excess allele-sharing in each of the three strata (GENEHUNTER Version 2.0). 17 Non-para- Narrow Phenotype: schizophrenia and schizoaffective disorder. **P-value Ͻ0.01; ***P-value Ͻ0.001; ****P-value Ͻ0.0001. These calculations used the non-parametric Z-all (NPL) statistic which computes the joint identity-by-descent probability among all affecteds within a family. The P-values presented were obtained from GENEHUNTER and were derived by computing the exact probability distribution of the overall Z-all score under the null hypothesis.
metric genome scan linkage results (narrow phenotype) are presented in Table 1 . Analyses indicate differential contributions by the three strata to linkage evidence on chromosomes 8 and 13 and provide evidence for previously unreported regions. The most significant allele sharing across the genome in seven SSPD families occurs on chromosome 8p21 (D8S1771) (NPL = 5.04, P = 0.000002) and all seven families exhibited allele sharing at D8S1771. The evidence for allele sharing among schizophrenic subjects is more significant in this SSPD group than in all 54 families or in either the PAD or Other sub-strata (54 families: P = 0.0001; PAD families, P = 0.04; Other families, P = 0.04). The chromosome 8p region implicated in the SSPD analyses remains broad (NPLϾ3.00 over 11 cM). Other evidence for susceptibility loci in these families was found in chromosomal region 1p21 (D1S495) (P = 0.006), in the HLA region on 6p21 (D6S1051) (P = 0.014), and in our previously recognized 13q32 region (D13S174) (P = 0.010) ( Table 1) .
Given the significantly increased allele sharing in the SSPD families for chromosome 8p21 (P = 0.000002), we undertook additional analyses in order to tease out the potential contribution of specific spectrum personality disorders (schizoid, spectrum, schizotypal) to the linkage in this region. We systematically tested three broadened phenotypes: (1) schizophrenia (SZ), schiMolecular Psychiatry zoaffective disorder (SZA), plus schizoid and schizotypal; (2) SZ, SZA, and paranoid; and (3) SZ, SZA, and schizoid, schizotypal, and paranoid. The unknown category included individuals with PAD and included schizotypal, schizoid or paranoid personality disorders when they were not considered in the affected category. The results of the analyses are reported in Table  2 . The largest increase in the evidence for allele sharing in the SSPD families occurs when the six individuals with a paranoid personality disorder are included in the affected category (NPL = 6.17, P = 0.0000008 from NPL = 5.04, P = 0.000002).
Non-parametric linkage analyses conducted in the recomputed genome scan for the PAD strata revealed that the most significant allele sharing in the genome between affected subjects in these six families is on chromosomes 22q13.1 (D22S1268) (NPL = 2.98, P = 0.004) and 3p25-24.3 (D3S1297) (NPL = 2.71, P = 0.008) with also modest support for the 8p21 locus (P = 0.04) and the 13q32 locus (P = 0.02) ( Table 2) .
Non-parametric linkage analyses in 36 families in the Other strata revealed the greatest genome-wide allele sharing at chromosome 13q32 (P = 0.00029). Four other regions exhibited P-values less than 0.01: 7p, 10q, 19q13 and 22q. The chromosome 19q13 evidence occurred at marker D19S220, about 4 cM from APOE, a potential candidate for Alzheimer's disease and PD: personality disorder(s). Three individuals fit criteria for more than one SSPD. One individual fit criteria for all SSPD. Note: One family met the selection criteria for inclusion in both the PAD and SSPD subgroups of families. We examined the effect this family had on our results by reanalyzing the data with this family excluded. In both the PAD and the SSPD groups, evidence for linkage at the peak NPL score did not change in a significant way. schizophrenia. Our previously reported chromosome 14 evidence 7 appears to be restricted to this remaining group.
Stratification could impact the interpretation of Pvalues due to the issue of multiple testing of each marker. These stratified analyses were hypothesisdriven and one could argue that no correction for multiple testing is required. Otherwise, two possible corrections to apply before declaring significance are: (1) multiply the P-value for a marker by 3, the number of tests for each marker (Bonferroni correction); or (2) decrease the NPL statistic by the log(3) as recommended by Kidd and Ott, 1984 . 18 Applying these corrections to the significant results for 8p21 (NPL 5.04, P = 0.000002) in the spectrum group leads to a corrected NPL of 4.5, or a P-value of 0.000006, and the finding remains significant.
We explored the possibility that there may be clinically observable differences in the expression of the schizophrenia phenotype in schizophrenic subjects in the SSPD subgroup when compared to subjects in the other two strata. There were no differences in the symptom profiles or in the rates of maternally vs paternally inherited pedigrees (details available on website: www.med.jhu.edu/epigen/stratification). Our inability to detect differences between the schizophrenic subjects in these genetically more homogenous groups may be due to the relatively small number of probands in each strata. In a recently reported paper, Kendler et al, 19 distinguished 8p-linked families from 8p-unlinked families based on clinical features associated with classical dementia praecox using a large Irish multiplex schizophrenia sample (265 pedigrees) exhibiting linkage to the chromosome 8p region. 5 Stratification of our genome scan data based on the psychiatric status of the non-schizophrenic relatives has increased the evidence for a susceptibility locus on chromosome 8p21 and has identified potential new regions. The analyses suggest that individuals with paranoid personality disorder may share the genetic susceptibility in the chromosome 8p region important for the SSPD families. We have hypothesized that cosegregating related phenotypes in multiplex schizophrenia families would provide a basis for stratification yielding genetically more homogeneous groups. These data suggest this is a promising strategy.
Identification of chromosomal regions linked to identifiable subgroups of families with schizophrenia is a step towards identifying the genetic etiologies associated with this complex disorder. Confirmation of this stratified approach in independent studies will be necessary.
Methods

Clinical and genetic
The majority of the multiplex families were ascertained through probands from a systematic sample of schizophrenic patients in the Maryland Epidemiologic Sample (MES). 20 A few additional families were identified through referrals from other investigators. Consensus diagnostic procedures (DSM-IV criteria) were followed using direct interview of each subject. Further details concerning sample characteristics, diagnostic procedures, genome scan marker maps and genotyping procedures are available in Blouin et al, 1998. 7 
Statistical
We performed non-parametric multipoint linkage analyses using the computer program GENEHUNTER version 2.0. GENEHUNTER estimates the statistical significance of sharing alleles identical-by-descent between all affected individuals (NPL or Z-all statistic). Using established criteria, 21 linkage evidence at a single point in the genome is considered significant whenever the P-value is 2.2 × 10 −5 . The evidence is considered suggestive whenever the P-value is between 2.2 × 10 −5 and 7.4 × 10 .
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